Cuál es el porcentaje de mujeres en perimenopausia global
1.1 mil millones de mujeres estarán en o tras la transición menopáusica para 2025, con 47 millones entrando en perimenopausia cada año.
26 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 26 of 26 clinical reviews.
1.1 mil millones de mujeres estarán en o tras la transición menopáusica para 2025, con 47 millones entrando en perimenopausia cada año.
Estrogen fluctuations during perimenopause increase the risk of new-onset depression, anxiety, and brain fog. Learn how clinicians diagnose and treat the mental health overlap.
Evidence-based guide for caregivers and families supporting someone through perimenopause, covering communication strategies, treatment literacy, mental health support, and clinical resources.
A clinical guide to the conditions that commonly co-occur with perimenopause, including thyroid disease, metabolic syndrome, mood disorders, sleep disturbance, and cardiovascular risk, with guidance on what to screen for and when to escalate care.
Perimenopause is misdiagnosed as depression, thyroid disease, anxiety, ADHD, and more. Learn which conditions get confused, why labs mislead, and how to get the right diagnosis.
A step-by-step perimenopause diagnostic algorithm covering STRAW+10 staging, lab workup, differential diagnosis, and treatment initiation based on major society guidelines.
A deep look at the emerging biological mechanisms driving perimenopause, including neuroinflammation, mitochondrial dysfunction, and kisspeptin signaling, with primary-source citations and clinical implications.
A clinical review of the latest perimenopause research, including neurokinin-3 receptor antagonists, novel biomarkers, combination HRT trials, and updated society guidelines shaping treatment in 2025 and beyond.
A clinical guide to resistance training, high-intensity intervals, and bone-loading exercise during perimenopause, with an evidence-boundary map and a clinician-discussion framework for individualizing the protocol.
A stage-by-stage guide to the real costs of perimenopause care, from early irregular cycles through late-stage vasomotor symptoms, including medication costs, lab work, and when to seek specialist care.
A guide to choosing between low-dose HRT, combined oral contraceptives, and non-hormonal therapies for perimenopause, based on current NAMS, Endocrine Society, and ACOG guidelines.
Learn how genetics and family history shape perimenopause timing, symptom severity, and treatment options. Evidence-based guidance from the HealthRX.com medical team, with citations to primary research.
A side-by-side comparison of major society guidelines for diagnosing and treating perimenopause, including hormone therapy recommendations from NAMS, the Endocrine Society, AACE, and USPSTF.
A comprehensive clinical history of perimenopause treatment from the 1960s through today, covering hormone therapy, the WHI trial fallout, and current evidence-based guidelines for managing symptoms.
Evidence-based nutrition, exercise, and lifestyle strategies for managing perimenopause symptoms, backed by major society guidelines and clinical trial data.
How partners and family members can support someone through perimenopause, including symptom education, communication strategies, and when to encourage professional care.
Black, Hispanic, and Asian women experience perimenopause differently from white women in symptom burden, duration, and access to care. Learn what the research shows and what clinical guidelines recommend.
Beyond hot flashes and irregular periods, perimenopause can present as new-onset seizures, auditory changes, autonomic dysfunction, and more. Learn the uncommon signs, their mechanisms, and evidence-based management.
Perimenopause costs the U.S. Economy billions each year through lost productivity, higher healthcare utilization, and workforce attrition. This evidence-based guide covers the full economic burden, what drives it, and what clinical interventions change the numbers.
Learn how to stop perimenopause treatments safely, including HRT, low-dose oral contraceptives, and non-hormonal therapies. Evidence-based tapering protocols, withdrawal timelines, and society guideline recommendations.
A guideline-based treatment algorithm for perimenopause: first-line, second-line, and third-line options for vasomotor symptoms, cycle irregularity, mood disturbance, and bone protection, with dosing, evidence grades, and society recommendations.
Learn exactly what counts as treatment failure in perimenopause, how to recognize it across HRT, oral contraceptives, and non-hormonal options, and what clinical guidelines say about next steps.
A guide to identifying, evaluating, and enrolling in perimenopause clinical trials, covering eligibility criteria, trial phases, HRT, non-hormonal options, and how to match your symptom profile to open studies.
A clinical guide to preparing for your first perimenopause appointment. Learn what symptoms to track, which lab tests to expect, and which treatments your doctor may discuss, all backed by major society guidelines.
Perimenopause is an adult phenomenon, but early-onset and adolescent hormonal transitions share overlapping biology. Learn how age shapes diagnosis, symptoms, and treatment across the lifespan.
A guide covering perimenopause symptoms, treatment options, and the specific signs that mean you need a second medical opinion. Includes real trial data, society guidelines, and decision frameworks.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.